Atossa Genetics, Inc. is a healthcare company developing and marketing cellular and molecular diagnostic risk assessment products for breast cancer. The company’s diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and monitor potential recurrence. For more information, visit the company’s website at www.atossagenetics.com.